Cyclin D1 (G870A) polymorphism and breast cancer risk in an Iranian population
DOI:
https://doi.org/10.47743/jemb-2024-153Keywords:
Breast cancer; ccnd1; polymorphismAbstract
Background and Objective: Cyclins are the key regulator of the cell cycle and their over-expression has been seen in many cancers including breast cancer. Cyclin D1 is an oncoprotein encoded by CCND1 gene located on chromosome 11 (11q) which regulates cell cycle in shifting from G1 to S phase. It’s the main target for steroids and mitogenic growth hormones in breast epithelial cells. This study aimed to evaluate the relationship between Cyclin D1 G870A polymorphism and breast cancer risk in a population in the north of Iran.
Methods: Whole blood samples collected from 82 patients with breast cancer and 66 healthy women. DNA was extracted and genotyping was performed by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) technique.
Results: Genotypic prevalence of AA, AG, GG genotypes among patients were 40.2%, 35.3% and 24.4% and in controls were 30%, 47%, 23%, respectively. There was no significant difference in CCND1 G870A genotype polymorphism between patients and control group (p=0.32). Also, allelic prevalence of A and G alleles in breast cancer patients were 58% and 42%, in controls were 54% and 46%, respectively. The present study showed that there is no significant association between CCND1 G870A polymorphism with the risk of breast cancer.
Conclusion: The results of this study revealed that there is no significant association between CCND1 G870A genetic polymorphism and the risk of breast cancer in the population of the north of Iran. More studies with larger samples of cases and controls would be beneficial.
References
Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, et al (2008). Cancer is a preventable disease that requires major lifestyle changes. Pharm Res; 25(9):2097-116. DOI: 10.1007/s11095-008-9661-9
Bedewy AM, Mostafa MH, Saad AA, El-Maghraby SM, Bedewy MM, et al (2013). Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer. J BUON; 18(1):227-38. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23613410/.
Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, et al (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene; 11(5):1005-11. Retrieved from https://pubmed.ncbi.nlm.nih.gov/7675441/.
Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, et al (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene; 8(8):2127-33. Retrieved from https://pubmed.ncbi.nlm.nih.gov/8336939/.
Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E (2001). Cyclin proteolysis as a retinoid cancer prevention mechanism. Ann N Y Acad Sci; 952:13-22. DOI: 10.1111/j.1749-6632.2001.tb02724.x
Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J (2007). Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer; 55(1):1-14. DOI: 10.1016/j.lungcan.2006.09.024
Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B (2003). Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res; 23(5b):4257-9. Retrieved from https://pubmed.ncbi.nlm.nih.gov/14666635/.
Gupta VK, Feber A, Xi L, Pennathur A, Wu M, et al (2008). Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma. Clin Cancer Res; 14(23):7804-12. DOI: 10.1158/1078-0432.CCR-08-0744
Inoue K, Fry EA (2015). Aberrant expression of cyclin D1 in cancer. Sign Transduct Insights; 4:1-13. DOI: 10.4137/STI.S30306
John RR, Malathi N, Ravindran C, Anandan S (2017). Mini review: Multifaceted roleplayed by cyclin D1 in tumor behavior. Indian J Dent Res; 28,187-192.DOI: 10.4103/ijdr.IJDR_697_16
Kazemi M, Salehi Z, Chakosari RJ (2009). TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res; 18(1):25-30. DOI: 10.3727/096504009789745629
Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene; 25(11):1620-8. DOI: 10.1038/sj.onc.1209371
Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, et al (2003). The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat; 82(3):165-8. DOI: 10.1023/B:BREA.0000004372.20461.33
Lundgren K, Holm K, Nordenskjold B, Borg A, Landberg G (2008). Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res; 10(5):R81. DOI: 10.1186/bcr2150
Mashayekhi F, Yousefi M, Salehi Z, Saedi HS, Pournourali M (2015). The association of ApE1 -656T>G and 1349T>G polymorphisms with breast cancer susceptibility in northern Iran. Cell Mol Biol (Noisy-le-grand); 61(4):70-4. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26314200/.
Mohammaddoust S, Salehi Z, Saeidi Saedi H (2018). SEPP1 and SEP15 gene polymorphisms and susceptibility to breast cancer. Br J Biomed Sci; 75(1):36-9. DOI: 10.1080/09674845.2017.1333241
Mohammedi L, Doula FD, Mesli F, Senhadji R (2019). Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters. Afr Health Sci; 19(2):2140-6. DOI: 10.4314/ahs.v19i2.38
Naidu R, Yip CH, Taib NA (2008). Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma; 55(2):87-95. Retrieved from https://pubmed.ncbi.nlm.nih.gov/18237245/
Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL (2003). Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat; 78(3):323-35. DOI: 10.1023/a:1023033708204
Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H (2008). Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev; 17(10):2773-81. DOI: 10.1158/1055-9965.EPI-08-0169
Palmero I, Peters G (1996). Perturbation of cell cycle regulators in human cancer. Cancer Surv; 27:351-67. Retrieved from https://pubmed.ncbi.nlm.nih.gov/8909810/.
Pandey A, Bahl C, Sharma S, Singh N, Behera D (2018). Functional role of CyclinD1 polymorphism (G870A) in modifying susceptibility and overall survival of North Indian lung cancer patients. Tumori; 104(3):179-87. DOI: 10.1177/0300891617753477
Ramos-Garcia P, Ruiz-Avila I, Gil-Montoya JA, Ayen A, Gonzalez-Ruiz L, et al (2017). Relevance of chromosomal band 11q13 in oral carcinogenesis: An update of current knowledge. Oral Oncol; 72:7-16. DOI: 10.1016/j.oraloncology.2017.04.016
Salehi Z, Afzali S, Shabanipour S, Rahimi A (2015). Evaluation of FGFR2 gene polymorphism in women with breast cancer. Cell Mol Biol (Noisy-le-grand); 61(2):94-7. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26025410/.
Salimi S, Shahrakipour M, Hajizadeh A, Mokhtari M, Mousavi M, et al (2017). Cyclin D1 G870A polymorphism: Association with uterine leiomyoma risk and in silico analysis. Biomed Rep; 6(2):237-41. DOI: 10.3892/br.2016.830
Sherr CJ (1996). Cancer cell cycles. Science; 274(5293):1672-7. DOI: 10.1126/science.274.5293.1672
Soleimani Z, Kheirkhah D, Sharif MR, Sharif A, Karimian M, et al (2017). Association of CCND1 Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-Analysis. Pathol Oncol Res; 23(3):621-31. DOI: 10.1007/s12253-016-0165-3
Takano Y, Takenaka H, Kato Y, Masuda M, Mikami T, et al (1999). Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res Clin Oncol; 125(8-9):505-12. DOI: 10.1007/s004320050309
Wen L, Hu YY, Yang GL, Liu DX (2014). CCND1 G870A polymorphism contributes to the risk of esophageal cancer: An updated systematic review and cumulative meta-analysis. Biomed Rep; 2(4):549-54. DOI: 10.3892/br.2014.286
Xie M, Zhao F, Zou X, Jin S, Xiong S (2017). The association between CCND1 G870A polymorphism and colorectal cancer risk: A meta-analysis. Medicine (Baltimore); 96(42):e8269. DOI: 10.1097/MD.0000000000008269
Yang L, Qu B, Xia X, Kuang Y, Li J, et al (2017). Impact of interaction between the G870A and EFEMP1 gene polymorphism on glioma risk in Chinese Han population. Oncotarget; 8(23):37561-7. DOI: 10.18632/oncotarget.16581
Zhang Y, Zeng X, Lu H, Ji H, Zhao E, et al (2016). Association between cyclin D1 (CCND1) G870A polymorphism and gastric cancer risk: a meta-analysis. Oncotarget; 7(40):66109-18. DOI: 10.18632/oncotarget.11848
Downloads
Published
How to Cite
License
Copyright (c) 2024 Khosrow Keshavarz Safiei, Farhad Mashayekhi, Hamid Saeidi saedi
This work is licensed under a Creative Commons Attribution 4.0 International License.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. The journal allows readers to read, download, copy, distribute, print, search, link to the full texts or use the articles for any other lawful purpose.
The authors are the sole copyright owners of the published articles. The articles are distributed under the CC BY 4.0 license to the readers.
The readers are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Reviewer Recognition Service. Forward your thank you e-mail to 
